The Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional organization—offers readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly changing issues in practice and research. JNM—the flagship publication of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)—ranked fifth place amongst all 128 medical imaging journals in its category, according to new data released in the 2018 Journal Citation Reports© published by Web of Science - Clarivate Analytics. JNM—a peer-reviewed, monthly publication—earned an impact factor of 7.439. Web of Science - Clarivate Analytics measures a journal’s impact—or significance—based on the number of article citations compared to the total number of articles published. The impact factor—a quantitative measure of the frequency with which an article in a journal is cited—is used to gauge the overall influence of a journal within scientific, professional and academic communities. The impact factor is often used as a measure of the quality and influence of medical journals among researchers. For more than 45 years, Thomson Reuters has provided a systematic and objective way for librarians, researchers and other decision-makers to measure influence in the global research community." The Journal Citation Report also publishes several other measurements for journals, including the total citations, immediacy index, and five-year impact factor. The Journal of Nuclear Medicine is available online at http://jnm.snmjournals.org. Print copies are available for purchase at $58 per copy. To order a copy, contact the SNMMI Subscription Services at subscriptions@snmmi.org or telephone 1-800-513-6853. A 2018 online subscription to the journal—including full-color design, full access to archives, and access to articles online ahead of print—costs $383 for individuals and $877 for institutions.

 JNM Ahead of Print,

Multiparametric 18F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?

Rationale: To assess whether there are differences in multiparametric 18F-fluorodeoxyglucose positron emission tomography–magnetic resonance imaging (18F-FDG PET-MRI) biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this IRB-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET-MRI of the breast at 3T with dynamic contrast-enhanced...

JNM Ahead of Print

7h

PET imaging of tumor PD-L1 expression with a highly specific non-blocking nanobody

Rationale: Although immunotherapy through programmed death 1 / programmed death ligand 1 (PD-1/PD-L1) checkpoint blockade has shown impressive clinical outcomes, not all patients respond to it. Recent studies have demonstrated that the expression level of PD-L1 in tumors is one of the factors that correlate with the PD-1/PD-L1 checkpoint blockade therapy. Herein, a novel 68Ga-labeled nanobody tracer, 68Ga-NOTA-Nb109, was designed and developed for specific and noninvasive imaging of PD-L1 expression...

JNM Ahead of Print

7h

Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer

Targeted radiopharmaceutical therapy (TRT) employing α-particle radiation is a promising approach for treating both large and micrometastatic lesions. We developed prostate-specific membrane antigen (PSMA)-targeted low-molecular-weight (LMW) agents for 212Pb-based TRT of patients with prostate cancer (PC) by evaluating the matching -emitting surrogate, 203Pb. Methods: Five rationally designed LMW ligands (L1-L5) were synthesized using the lysine-urea-glutamate (Lys-urea-Glu) scaffold and PSMA...

JNM Ahead of Print

7h

Image quality and semi-quantitative measurements of the Siemens Biograph Vision PET/CT: Initial experiences and comparison with Siemens Biograph mCT PET/CT

In May 2018 the new Biograph Vision PET/CT (Siemens Healthineers, Knoxville, USA) was introduced at the University Medical Center Groningen. This study evaluated the initial experiences with this new PET/CT system in terms of perceived image quality and semi-quantitative analysis in comparison to the Biograph mCT (Siemens Healthineers, Knoxville, USA) as a reference. Methods: A total of 20 oncological patients were enrolled and received a single 18F-FDG injected dose of 3 MBq/kg followed by a...

JNM Ahead of Print

7h

Matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy

Purpose: 18F-labeled prostate-specific membrane antigen (PSMA)-ligand positron emission tomography (PET) has several principal advantages compared to 68Ga-PSMA-11. The purpose of this retrospective study was to evaluate the frequency of non-tumor related uptake and the detection efficacy comparing 68Ga-PSMA-11 and 18F-PSMA-1007 PET/computed tomography (CT) in recurrent prostate cancer (PC) patients. Methods and Materials: 102 patients with biochemical recurrent PC after radical prostatectomy undergoing...

JNM Ahead of Print

7h